GenoVise, a London-based biotechnology startup, has secured $150 million in Series B funding to accelerate the development of its personalized longevity platform, which uses AI to analyze a patient's genome and prescribe custom cellular repair therapies.
The round was led by SoftBank Vision Fund 2 and includes participation from several prominent UK venture capital firms. GenoVise plans to open its first flagship 'Longevity Clinic' in Mayfair next year.
"We are moving from treating disease to engineering health," said the founder of GenoVise.
